What Early Outpatient Experience With Xanomeline/Trospium May Teach Us About Schizophrenia Care

Schizophrenia is a complex psychiatric condition that can affect perception, thinking, motivation, communication, and daily functioning. Although several medications are available, treatment can become more complicated when a person has coexisting medical or psychiatric conditions, takes multiple medications, or experiences side effects that limit available options. This article reviews early outpatient observations involving xanomeline/trospium and the questions that can arise when a newer treatment is introduced into everyday psychiatric care.

Xanomeline/trospium, also known by the brand name Cobenfy, was approved by the U.S. Food and Drug Administration in September 2024 for the treatment of schizophrenia in adults. Unlike medications that primarily act by directly blocking dopamine receptors, xanomeline targets muscarinic acetylcholine receptors involved in brain pathways related to dopamine regulation, cognition, learning, and psychosis. Trospium is included to help reduce certain effects of xanomeline outside the brain.

The clinical trials supporting approval were conducted under controlled conditions. Many participants stopped previous antipsychotic medications before beginning xanomeline/trospium, and treatment was started and adjusted in a hospital setting. Outpatient practice can look very different. People may have a long history of treatment, take several medications at once, or face safety concerns that make abruptly discontinuing an existing medication inappropriate.

In a case report published in Frontiers in Psychiatry, Maxwell Zachary Price and Dr. Richard Louis Price described their early experience using xanomeline/trospium among 40 adult outpatients with schizophrenia and coexisting conditions. The authors presented three representative cases to explore practical issues that were not fully addressed in the original registration trials. These cases were intended to generate clinical observations and questions rather than establish that the treatment would produce the same results in other patients.

One major theme was the importance of distinguishing between different types of side effects. Xanomeline may be associated with cholinergic effects such as nausea, vomiting, or diarrhea, while trospium may contribute to anticholinergic effects such as constipation, reflux, or urinary retention. The report emphasizes that clinicians must consider the full medication regimen because other prescribed drugs may increase, reduce, or complicate these effects.

The cases also illustrate how polypharmacy can affect treatment response. Some medications may have overlapping anticholinergic properties, while others may interact with the way xanomeline is processed in the body. In outpatient care, introducing a new treatment may therefore require gradual changes, close monitoring, and careful consideration of whether other medications remain necessary. These decisions must be individualized and should not be generalized from a small group of cases.

The authors also observed possible changes in areas such as concentration, communication, memory, motivation, and social engagement. Because the report was observational and did not use a controlled comparison group or standardized symptom measurements, these observations cannot establish that xanomeline/trospium caused the reported improvements. They do, however, raise questions about whether muscarinic treatments may eventually have broader relevance to cognitive and functional symptoms associated with schizophrenia and certain coexisting conditions.

The article acknowledges several important limitations. It describes a small number of selected cases, the observations were not collected through a randomized clinical trial, and the study did not include formal symptom scores before and after treatment. Selection bias may also have influenced which cases were presented. Larger and more rigorous studies are needed to determine how well these early findings apply to the broader population of people living with schizophrenia.

The broader lesson is that the transition from clinical trials to routine psychiatric practice requires careful implementation. A medication’s mechanism and trial results are only part of the picture. Coexisting conditions, medication interactions, side effects, prior treatment response, and an individual’s safety needs can all influence how a treatment is used and whether it is tolerated. Emerging therapies may expand the options available in schizophrenia care, but their role must continue to be evaluated through clinical research and individualized medical judgment.

Sources and Disclosures

This blog post discusses themes from: Price MZ, Price RL. "Early outpatient clinical experience with xanomeline and trospium chloride for schizophrenia: a case report." Frontiers in Psychiatry. Published June 20, 2025. 16:1630574. doi: 10.3389/fpsyt.2025.1630574.

Funding: The authors reported that no financial support was received for the research or publication of the original article.

Conflict of interest: Dr. Richard Louis Price, an author of the original case report and a member of Rebu's clinical leadership, has served as a speaker for AbbVie, Alkermes, Allergan, Axsome, Biogen, Bristol-Myers Squibb, Idorsia, Intracellular, Janssen, Jazz, Lundbeck, Neuronetics, Otsuka, Sage, Supernus, Teva, and Vanda. The other author reported no commercial or financial relationships that could be construed as a potential conflict of interest.

Medical disclaimer: This blog post is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to recommend or promote any specific medication, therapy, provider, or treatment plan. Medication and treatment decisions should be made by a licensed clinician based on an individual patient’s history, symptoms, risks, benefits, and clinical needs.